Buy the Dip Monday: 31% Drawdowns, 12% Earnings Yields, and Net Insider Buying

This Week's Setup

This week's dip list mixes rate-sensitive banks with commodity cash generators and a profitable biotech, all tied together by double-digit earnings yields or deep drawdowns with insider participation.

BANC still prices below tangible book, CNX and EXEL show the strongest insider bid-ask skews, FSLR pairs a 31% drawdown with 24% revenue growth and a new U.S. finishing plant expansion, and NEM, INCY, PTCT, and ACAD fill out gold and biotech sleeves where ROIC and margins already screen institutional-grade.

The 8 Names

1. Banc of California, Inc. (BANC)

Stock Pixie Score 10.0/10 | P/E 15.19 | FCF yield 8.6% | Earnings yield 6.6%

The valuation setup here is a bank trading at 0.91× tangible book with an 8.6% free cash flow yield and revenue growth of 11.9% year-over-year, well below the 15 P/E that typically prices expanding franchises in California markets.

Insider selling dominates the six-month window: 91.5% of transactions by share count were sales, with net outflows of 12.6 million shares even as recent Form 4 filings from Helmick, Varischetti (two filings in late March), and others registered activity.

Short interest at 6.2% of float and a debt-to-equity ratio of 0.89 mean any credit-cycle surprise or commercial real estate headline could trigger a re-rating faster than the 28% analyst upside target suggests.

2. CNX Resources Corporation (CNX)

Stock Pixie Score 10.0/10 | P/E 9.78 | FCF yield 9.7% | EV/EBITDA 5.55

A natural gas producer with 10.2% earnings yield, 48.9% revenue growth, and 11.1% ROIC trades at less than 10× earnings and 5.6× EV/EBITDA, a valuation gap that assumes structurally lower gas prices despite recent pipeline infrastructure expansion in Appalachia.

Insider buying from director Lally-Green in late March (Form 4 period March 25) contributed to a 5.29 insider score and net purchases of 383,371 shares over six months, the strongest directional signal on this week's list.

Short interest at 13.3% of float and consensus analyst targets 4.6% below the current price flag Wall Street skepticism on natural gas pricing power through 2026.

3. Exelixis, Inc. (EXEL)

Stock Pixie Score 10.0/10 | P/E 15.84 | FCF yield 7.4% | ROIC 54.1%

A biotech with 54% return on invested capital, 96% gross margins, and 7% revenue growth throws off 7.4% free cash flow yield and trades at 15.8× earnings, well below the normalized 10-year P/E of 30.6.

Insiders bought 80.5% of transactions by count over six months, adding 2.16 million net shares and generating an 8.03 insider score, the highest directional conviction among this week's pipeline-stage names.

The normalized P/E of 30.6 and short interest at 12.5% of float reflect market uncertainty about royalty durability and competitive pressures in kidney cancer, where Exelixis faces biosimilar and next-generation rivals.

4. First Solar, Inc. (FSLR)

Stock Pixie Score 10.0/10 | P/E 13.82 | Revenue growth 24.1% | Drawdown -31.3%

A 31% drawdown in a solar manufacturer with 24% revenue growth, 40.6% gross margins, and 17.5% ROIC has created a 13.8× P/E entry against a 27.5% analyst upside target to $250.57.

First Solar announced a 3.7 GW U.S. finishing plant expansion (news: "First Solar Is Up 5.1% After Announcing New 3.7GW U.S. Finishing Plant Expansion"), which directly supports the backlog visible in the 24% revenue growth and validates the $250 consensus target.

Insider selling from Verma, Theurer (both March 11), and Sweeney (April 1) resulted in net outflows of 13,278 shares and a 4.99 insider score, signaling management is taking profits into the rally off the $196 trough.

The debt-to-equity ratio of 0.07 is pristine, but 7.7% short interest and EV/EBITDA of 8.8× reflect skepticism that solar pricing and margin expansion can sustain a 13× forward multiple if subsidy tailwinds reverse.

5. Incyte Corporation (INCY)

Stock Pixie Score 10.0/10 | P/E 14.94 | FCF yield 7.0% | ROIC 80.2%

An 80% return on invested capital, 92.7% gross margins, and 21.2% revenue growth in a biotech trading at 14.9× earnings and 10.8× EV/EBITDA is a valuation disconnect typically reserved for ex-growth franchises, not expanding oncology platforms.

Incyte announced a clinical collaboration with Adagene to evaluate muzastotug in combination with INCA33890 (a TGFβR2×PD-1 bispecific) in microsatellite stable colorectal cancer (news: "Adagene, Incyte to Evaluate Muzastotug, INCA33890 in Microsatellite Stable Colorectal Cancer"), a pipeline expansion that addresses one of oncology's hardest-to-treat subsets.

Insider selling from Harrigan, Clancy (both April 2), and Trotta (March 26) resulted in net outflows of 280,177 shares and an insider percentage sell of 8.9%, offsetting the 1.9% buy rate and signaling management profit-taking after the 6.2% rally on positive povorcitinib data.

The normalized 10-year P/E of 35.7 and 6.6% short interest reflect market concern that the current 14.9× multiple is unsustainably low only if royalty streams and Jakafi franchise durability prove out through 2027.